Shingle and Varicella vaccines at Curevo 6000x4000
15 Sep

Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101

curevovaccine News, Vaccines No Comments
SEATTLE–(BUSINESS WIRE)–Curevo Vaccine, a clinical stage biopharmaceutical company developing next generation vaccines for patients with infectious disease of global importance, today announced antibody response data from its completed Phase 1 study investigating the safety, tolerability, and immune system response of CRV-101 in several formulations. The administration of Curevo’s adjuvanted sub-unit Shingles investigational vaccine resulted in a robust antibody response against…
Continue Reading
Vaccines 1626 x 1080
26 Sep

Curevo Vaccine Announces Interim Results of Phase I Clinical Trial of CRV-101

curevovaccine News, Press Releases, Vaccines No Comments
SEATTLE–(BUSINESS WIRE)–Curevo, Inc., a Seattle-based biotechnology company invested in by GC Pharma, one of the largest therapeutic protein manufacturers in the world, has announced encouraging preliminary Phase I safety and tolerability results of their Shingles vaccine candidate, CRV-101. Interim trial results demonstrating a promising safety and tolerability profile of the vaccine in 90 healthy adults ≥18 to <50 were presented…
Continue Reading
GC Pharma to Establish Curevo 1080x1080
18 May

GC Pharma to Establish Curevo

curevovaccine News, Vaccines No Comments
GC Pharma to Establish Curevo – a Seattle-based New Company Dedicated to Development of New Vaccines GC Pharma, IDRI and MIBR Bringing Together to Develop Innovative Vaccines GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced the establishment of Curevo Inc. (“Curevo”). The newly established Seattle-based company’s goal is to support GC…
Continue Reading
1 2